Description
Becton Dickinson Fuels Biologics Boom With 70+ GLP-1 Agreements; What Lies Ahead?
Becton, Dickinson and Company (BD) reported its third fiscal quarter results for 2025, highlighting both positive developments and challenges within the company. BD’s revenue grew by 8.5% to $5.5 billion, with organic growth at 3%. The adjusted gross margin increased by 50 basis points year-over-year to 54.8%, and the adjusted operating margin improved by 60 basis points to 25.8%. Adjusted diluted earnings per share (EPS) reached $3.68, surpassing expectations.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
